|
AA and Fountaine,
The results presented at ASCO were very preliminary BUT will encourage the oncologists to revisit Herceptin treatments in advance of a change in the FDA protocol.
I don't feel than clinical trials in this area are warranted as by the time the trials would be over it would be a non-issue. By then Herceptin by then will be FDA approved for adjuvant treatment.
Lets face it, there are several major medical and oncology seminars held yearly. I am sure that the progress of the clinical trials were discussed unofficially among the various oncologists attending these meetings. This information swayed many oncologists to prescribe Herceptin "off label" and we all are grateful for them doing this.
Also, approval from the FDA will in fact force coverage from the insurance companies.
|